Coronaviruses are a group of enveloped viruses with single-stranded non-segmented positive-sense RNA genomes. In
December 2019, SARS-CoV-2 appeared in China for the first time and quickly spread throughout the world. Although
certain medications suggested for other afflictions tend to be potentially effective for curing the infection, there is no
approved vaccination or drug available for this virus yet. Comprehension of the disease molecular pathogenesis could
provide useful tools for COVID-19 patients in surveillance, prognosis, treatment, vaccine development and therapeutic
targeting. The present research aims to summarize the association in COVID-19 patients between molecular dimensions
of comorbidities with clinical and preclinical information.
Developing an ACE2 inhibitor could be a possible therapeutic target. Plasmin is another possible candidate both in
diagnosis and treatment areas. All predicted biomarkers must be validated either through randomized clinical trials or
experimental assays before clinical application in patients.
Level of evidence: V